Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognizes and blocks vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates the growth of new blood vessels (angiogenesis).
Bevacizumab was the
first commercially available angiogenesis inhibitor. It stops tumor
growth by preventing the formation of new blood vessels by targeting
and inhibiting the function of a natural protein called vascular
endothelial growth factor (VEGF) that stimulates new blood vessel
formation.
The drug was first developed as a genetically engineered
version of a mouse antibody that contains both human and mouse
components. Genentech is able to produce the antibody in
production-scale quantities.
Blood vessels grow uncontrollably in cancer, retinal proliferation of diabetes in the eye, and other diseases. Bevacizumab can block VEGF-A from creating new blood vessels. Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of recurring glioblastoma multiforme, while treatment for initial growth is still in phase III clinical trial.
Further Reading
This article is licensed under the Creative Commons Attribution-ShareAlike License.
It uses material from the Wikipedia article on
"Bevacizumab"
All material adapted used from Wikipedia is available under the terms of the
Creative Commons Attribution-ShareAlike License.
Wikipedia® itself is a registered trademark of the Wikimedia Foundation, Inc.